Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (Q33908108)

29 July 2017

1 reference

title

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

4

1 reference

29 July 2017

6

P Tugwell

1 reference

29 July 2017

Z Ortiz

1

1 reference

29 July 2017

B Shea

series ordinal

2

1 reference

29 July 2017

M Suarez Almazor

series ordinal

3

1 reference

29 July 2017

G Wells

series ordinal

5

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

published in

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

CD000951

1 reference

Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Incorporating variations in the quality of individual randomized trials into meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Folate supplementation and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Biological effects of folic acid antagonists with antineoplastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Meta-analysis in medicine. Where we are and where we want to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Assessing the quality of randomized controlled trials. Current issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Folate supplementation in methotrexate-treated rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Efficacy of low-dose methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000951

10.1002/14651858.CD000951

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference